Literature DB >> 24986871

Extending the reach of nilotinib in chronic myeloid leukemia.

Michael J Mauro1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24986871      PMCID： PMC4077069          DOI： 10.3324/haematol.2014.106195

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  6 in total

1.  Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?

Authors:  Elias Jabbour; Hagop M Kantarjian; Susan O'Brien; Jianqin Shan; Alfonso Quintás-Cardama; Guillermo Garcia-Manero; Mary Beth Rios; Jorge E Cortes
Journal:  J Clin Oncol       Date:  2011-10-11       Impact factor: 44.544

2.  European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.

Authors:  David Marin; Dragana Milojkovic; Eduardo Olavarria; Jamshid S Khorashad; Hugues de Lavallade; Alistair G Reid; Letizia Foroni; Katayoun Rezvani; Marco Bua; Francesco Dazzi; Jiri Pavlu; Matthias Klammer; Jaspal S Kaeda; John M Goldman; Jane F Apperley
Journal:  Blood       Date:  2008-08-20       Impact factor: 22.113

3.  Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.

Authors:  R A Larson; A Hochhaus; T P Hughes; R E Clark; G Etienne; D-W Kim; I W Flinn; M Kurokawa; B Moiraghi; R Yu; R E Blakesley; N J Gallagher; G Saglio; H M Kantarjian
Journal:  Leukemia       Date:  2012-05-18       Impact factor: 11.528

Review 4.  Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.

Authors:  Michele Baccarani; Jorge Cortes; Fabrizio Pane; Dietger Niederwieser; Giuseppe Saglio; Jane Apperley; Francisco Cervantes; Michael Deininger; Alois Gratwohl; François Guilhot; Andreas Hochhaus; Mary Horowitz; Timothy Hughes; Hagop Kantarjian; Richard Larson; Jerald Radich; Bengt Simonsson; Richard T Silver; John Goldman; Rudiger Hehlmann
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

5.  Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily.

Authors:  Timothy P Hughes; Andreas Hochhaus; Hagop M Kantarjian; Francisco Cervantes; François Guilhot; Dietger Niederwieser; Philipp D le Coutre; Gianantonio Rosti; Gert Ossenkoppele; Clarisse Lobo; Hirohiko Shibayama; Xiaolin Fan; Hans D Menssen; Charisse Kemp; Richard A Larson; Giuseppe Saglio
Journal:  Haematologica       Date:  2014-02-14       Impact factor: 9.941

Review 6.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Authors:  Michele Baccarani; Michael W Deininger; Gianantonio Rosti; Andreas Hochhaus; Simona Soverini; Jane F Apperley; Francisco Cervantes; Richard E Clark; Jorge E Cortes; François Guilhot; Henrik Hjorth-Hansen; Timothy P Hughes; Hagop M Kantarjian; Dong-Wook Kim; Richard A Larson; Jeffrey H Lipton; François-Xavier Mahon; Giovanni Martinelli; Jiri Mayer; Martin C Müller; Dietger Niederwieser; Fabrizio Pane; Jerald P Radich; Philippe Rousselot; Giuseppe Saglio; Susanne Saußele; Charles Schiffer; Richard Silver; Bengt Simonsson; Juan-Luis Steegmann; John M Goldman; Rüdiger Hehlmann
Journal:  Blood       Date:  2013-06-26       Impact factor: 22.113
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.